Glenmark Life science IPO opens today. The Mumbai-headquartered company has set a price band at Rs 695- Rs 720 per equity share. The IPO will be live for three days till July. Glenmark Life Sciences is likely to make its debut on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 6. If you are interested in Glenmark Life Sciences IPO then here are things you should know.
Glenmark Life Sciences’ Rs 1,514 crore IPO, consists of a fresh issue of Rs 1,060 crore and an OFS of up to Rs 453 crore from existing shareholders.
Glenmark Life has leadership in select high-value non-commercialized APIs in chronic therapeutic areas. Leadership, a strong balance sheet, a growing business, and a high return on net worth (RoNW) of 46.71 percent. Add to that are reasonable valuations, which the brokerage said made it suggest a ‘subscribe’ on the issue. The company analysts have a positive approach to the IPO and are expecting a good performance through the subscriptions. Also, the research teams at different shareholders have recommended subscribing to the offer.
|IPO Open Date||Jul 27, 2021|
|IPO Close Date||Jul 29, 2021|
|Basis of Allotment Date||Aug 3, 2021|
|Initiation of Refunds||Aug 4, 2021|
|Credit of Shares to Demat Account||Aug 5, 2021|
|IPO Listing Date||Aug 6, 2021
About Glenmark Life Sciences
Glenmark Life Sciences is a leading manufacturer of high-value pharmaceutical ingredients for chronic health conditions. It was incorporated in 2011.
Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). Its products are being sold in India and also exported to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently.
The company develops, manufactures, and supplies –
APIs for cardiovascular disease (CVS), Central Nervous System Disease (Cns), Pain Management, Diabetes, Gastrointestinal Disorder, Anti-infectives, Other therapeutic areas.
It further operates in Contract Development and manufacturing operations (CDMO) to offer services to speciality Pharmaceutical companies.
Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
Export products in Europe, Latin America, North America, Japan, and the rest of the world.
A strong relationship with leading global generic companies.
Proven track record of strong financial performance.
High-quality product manufacturing with R&D infrastructure.
The company has a debt-to-equity of 1.3x with a debt of Rs 916 crore which includes Rs 800 crore payable to Glenmark Pharmaceuticals, post-IPO debt will be negligible.
The parent company Glenmark pharmaceuticals is the major client of this company.